Pfizer's $12.73 Billion Trading Day Lands 54th in Market Activity

On May 8, 2025, Pfizer's trading volume reached $12.73 billion, ranking 54th in the day's stock market activity. Pfizer's stock price increased by 0.79%.

Pfizer's stock price has been influenced by several recent developments. The appointment of Vinay Prasad as the new head of the FDA's Center for Biologics Evaluation and Research has raised questions about the future of cell and gene therapy regulation, which could impact Pfizer's gene therapy initiatives. Additionally, the FDA has expanded surprise inspections at foreign drug and food facilities, targeting double standards in overseas manufacturing oversight. This move could affect Pfizer's global supply chain and manufacturing processes.

Pfizer's CEO, Albert Bourla, has emphasized the importance of national security in US drug manufacturing. This focus on domestic production aligns with recent Trump administration policies aimed at fast-tracking US drug production and reducing reliance on imported medicines. These policies could have significant implications for Pfizer's operations and strategic decisions.

Pfizer's first-quarter earnings report showed an EPS of $0.92, beating the estimated $0.67. The company has also reaffirmed its FY2025 adjusted EPS guidance of $2.00 to $2.10. Despite the positive earnings report, Pfizer's COVID-19 windfall has shrunk, leading the company to expand its cost-cutting efforts. This shift in focus could impact Pfizer's future financial performance and stock price.

Pfizer has also been involved in collaborations to develop new cancer therapies. The company has partnered with Guardant Health to use a liquid biopsy platform for developing new cancer treatments. This collaboration could enhance Pfizer's oncology portfolio and drive future growth.